What's Behind The Slump In Pfizer Stock?

Core Insights - Pfizer stock (NYSE: PFE) has experienced a significant decline, marking its ninth consecutive day of losses and a total drop of −11%, resulting in a market capitalization loss of approximately $18 billion, bringing its current value to around $138 billion [2][4] - The stock is currently 3.8% lower than its closing price in 2024, contrasting sharply with the S&P 500's year-to-date return of 12.7% [3] - Despite positive developments such as strong Phase 3 trial results for a breast cancer treatment and a new acquisition in the weight management sector, investor confidence remains low due to serious revenue challenges, particularly from impending patent expiries on key drugs like Eliquis and Ibrance [4][5] Financial Performance - The current losing streak of PFE stock raises concerns among investors, indicating a potential shift in market sentiment or deeper underlying issues [7][8] - The Trefis High Quality Portfolio, which includes 30 stocks, has consistently outperformed its benchmark indices, suggesting that a diversified investment strategy may yield better returns and reduced risk compared to relying solely on PFE stock [6][8]